SSA
NBIX icon

Schonfeld Strategic Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.46M Sell
56,615
-33,357
-37% -$4.43M 0.05% 377
2025
Q4 		$12.8M Buy
89,972
+12,279
+16% +$1.78M 0.06% 289
2025
Q3 		$10.9M Buy
77,693
+4,748
+7% +$643K 0.06% 328
2025
Q2 		$9.17M Buy
72,945
+65,782
+918% +$7.54M 0.06% 365
2025
Q1 		$792K Sell
7,163
-37
-0.5% -$4.69K ﹤0.01% 1383
2024
Q4 		$983K Sell
7,200
-17,082
-70% -$2.11M 0.01% 1127
2024
Q3 		$2.8M Sell
24,282
-6,131
-20% -$841K 0.02% 750
2024
Q2 		$4.19M Sell
30,413
-17,281
-36% -$2.37M 0.03% 613
2024
Q1 		$6.58M Sell
47,694
-80,675
-63% -$11M 0.04% 538
2023
Q4 		$16.9M Buy
128,369
+99,360
+343% +$11.4M 0.11% 200
2023
Q3 		$3.26M Sell
29,009
-12,895
-31% -$1.36M 0.03% 673
2023
Q2 		$3.95M Sell
41,904
-52,258
-55% -$5.11M 0.03% 552
2023
Q1 		$9.53M Buy
94,162
+46,562
+98% +$4.85M 0.09% 295
2022
Q4 		$5.69M Sell
47,600
-21,843
-31% -$2.56M 0.05% 444
2022
Q3 		$7.38M Buy
69,443
+32,722
+89% +$3.32M 0.06% 406
2022
Q2 		$3.58M Sell
36,721
-36,986
-50% -$3.41M 0.03% 564
2022
Q1 		$6.91M Sell
73,707
-47,511
-39% -$4.03M 0.06% 346
2021
Q4 		$10.3M Buy
+121,218
New +$11.2M 0.09% 280
2021
Q3 		– Sell
-19,800
Closed -$1.93M – 2361
2021
Q2 		$1.93M Buy
+19,800
New +$1.9M 0.02% 721
2020
Q4 		– Sell
-36,551
Closed -$3.52M – 1764
2020
Q3 		$3.52M Buy
36,551
+31,592
+637% +$3.65M 0.07% 370
2020
Q2 		$605K Buy
4,959
+2,458
+98% +$272K 0.02% 742
2020
Q1 		$216K Sell
2,501
-22,183
-90% -$2.17M 0.01% 886
2019
Q4 		$2.65M Sell
24,684
-39,416
-61% -$4.13M 0.06% 293
2019
Q3 		$5.78M Buy
64,100
+26,200
+69% +$2.45M 0.17% 156
2019
Q2 		$3.2M Sell
37,900
-16,400
-30% -$1.35M 0.11% 213
2019
Q1 		$4.78M Sell
54,300
-49,489
-48% -$4.14M 0.17% 164
2018
Q4 		$7.41M Buy
103,789
+53,789
+108% +$5.15M 0.29% 85
2018
Q3 		$6.15M Sell
50,000
-5,000
-9% -$567K 0.27% 101
2018
Q2 		$5.4M Buy
55,000
+19,793
+56% +$1.77M 0.29% 98
2018
Q1 		$2.92M Buy
35,207
+4,238
+14% +$358K 0.22% 136
2017
Q4 		$2.4M Sell
30,969
-24,711
-44% -$1.69M 0.2% 144
2017
Q3 		$3.41M Buy
+55,680
New +$2.94M 0.31% 103
2017
Q2 		– Sell
-15,320
Closed -$664K – 709
2017
Q1 		$664K Buy
+15,320
New +$656K 0.07% 323
2016
Q4 		– Sell
-5,419
Closed -$274K – 614
2016
Q3 		$274K Sell
5,419
-81,244
-94% -$4.05M 0.05% 325
2016
Q2 		$3.94M Buy
+86,663
New +$3.99M 0.88% 17

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's NBIX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Neurocrine Biosciences (NBIX) stake by 37% in Q1 2026, selling an estimated $4.43M and leaving 56,615 shares worth $7.46M. The position accounts for 0.05% of the portfolio, ranked #377.

Schonfeld Strategic Advisors first reported a position in NBIX in Q2 2016 and has held it in 35 quarters since. The position peaked at $16.9M in Q4 2023. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Schonfeld Strategic Advisors held 56,615 shares of Neurocrine Biosciences worth $7.46M as of Q1 2026.
  • Schonfeld Strategic Advisors sold 33,357 Neurocrine Biosciences shares in Q1 2026, an estimated $4.43M.
  • Neurocrine Biosciences made up 0.05% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #377 holding.
  • Schonfeld Strategic Advisors first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 35 quarters since.
  • Schonfeld Strategic Advisors's Neurocrine Biosciences position peaked at $16.9M in Q4 2023.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.